Compounded GLP-1 medications and FDA policy in 2026

Expanded decision guide

A verified policy timeline is more useful than a slogan

FDA resolved the tirzepatide injection shortage in 2024 and the semaglutide injection shortage in 2025, and the related temporary enforcement periods ended. On April 1, 2026, FDA restated selected section 503A and 503B conditions. Exact dates and later agency updates should be checked in the official sources on this page. An old shortage headline is not a reliable statement of current policy.

The April 1, 2026 four-prescription enforcement position

For this duplication policy, FDA compares the API or APIs, whether the strength is the same, similar, or easily substitutable, and whether the commercially available product can be used by the prescribed route, subject to the documented significant-difference exception. FDA stated that, at that time, it did not intend to take action for the 503A condition limiting regular or inordinate compounding of commercially available product duplicates when a compounder fills four or fewer prescriptions of that compounded drug product during a calendar month. This is an enforcement position, not permission, FDA approval, or a statutory safe harbor. It does not waive the individual-patient prescription condition, the significant-difference rule when that exception is relied on, other federal requirements, state law, or FDA action for quality, safety, labeling, or other violations. Current FDA guidance and facts must be checked before relying on it.

Clinical rationale and the 503A significant-difference rule are separate

A clinician may have a medical reason to discuss a compounded option, but that conclusion alone does not satisfy the 503A significant-difference exception. When the exception is relied on, the prescriber must determine and document that the compounded drug contains a change that produces a significant difference for the identified patient compared with the commercially available product. The record should identify the change and why it matters to that patient.

The 503B bulks-list and shortage conditions

FDA's April 1 update said semaglutide and tirzepatide appeared neither on the 503B bulks list nor on FDA's drug shortage list. Under section 503B, an outsourcing facility generally may use a bulk drug substance only when the substance appears on the 503B bulks list, or when the drug made from that substance appears on the shortage list at the time of compounding, distribution, and dispensing. FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and later extended the comment period through July 30, 2026. As of July 16, 2026, this remained a proposal, not a final determination. The current lists and final agency record control.

What this means for one patient

Policy does not decide whether a medication is appropriate for a particular person. The visit must still review indication, contraindications, medicines, prior response, side effects, pregnancy plans, approved alternatives, and the reason for considering a preparation. Compounded semaglutide and tirzepatide remain not FDA-approved and not brand-identical, and results vary. A prescription and fulfillment cannot be promised before those facts and the patient's location are reviewed.

What to monitor over time

Monitor FDA's current compounding notices, the drug-shortage database, the dispensing pharmacy's license and public discipline, the exact label received, and any product-specific safety communication. For personal care, also monitor response, side effects, hydration, nutrition, and follow-up access with the prescriber.

Practical implications

Ask for the legal name of the pharmacy, the reason the prescription is being considered, the exact preparation and directions, separate costs, and the plan if the pharmacy cannot lawfully fill it. An answer may depend on facts that change, so current verification is more responsible than a permanent availability claim.